StockData
Metagenomi Therapeutics, Inc. logo

Metagenomi Therapeutics, Inc. (MGX) stock

MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.69−0.02 (-3.12%)

Close on Nov 13, 2026Market cap $26.13MP/E –Yield –

Earnings

Metagenomi Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 4, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$2.18M
-74.8% on a year earlier
EPS, Q3 FY2026
-$0.56
-$0.55 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Metagenomi Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 4, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026after the close$2.18M-74.8%-$0.56Release
Q2 FY2026ended Jun 30, 2026Aug 10, 2026during market hours–––Release
Q1 FY2026ended Mar 31, 2026May 11, 2026during market hours$1.25M-69.8%-$0.61Release
Q4 FY2025ended Dec 31, 2025Mar 5, 2026during market hours–––Release
Q3 FY2025ended Sep 30, 2025Nov 12, 2025before the open$8.66M-24.8%-$0.55Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025during market hours$8.51M–-$0.54Release
Q1 FY2025ended Mar 31, 2025May 13, 2025during market hours$4.13M-63.0%-$0.68Release
Q4 FY2024ended Dec 31, 2024Mar 17, 2025during market hours–––Release
Q3 FY2024ended Sep 30, 2024Nov 13, 2024during market hours$11.51M–-$0.51Release
Q2 FY2024ended Jun 30, 2024Aug 14, 2024before the open–––Release
Q1 FY2024ended Mar 31, 2024May 14, 2024during market hours$11.16M–-$1.19Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Metagenomi Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Metagenomi Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Metagenomi Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results
    Results
  2. Precision gene editing designed to deliver durable, curative medicines Corporate Presentation September 2026
    Update
  3. Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
    Results
  4. Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
    Results
  5. Precision gene editing designed to deliver durable, curative medicines Hemophilia A lead program | IND 2026 Corporate Presentation May 2026
    Results
  6. Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
    Results
  7. Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
    Update
  8. 8-K exhibit EX-99.2
    Update
  9. Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
    Results
  10. Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program
    Results
  11. Quarterly results release
    Results
  12. Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results
    Results
  13. Quarterly results release
    Results
  14. Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASCGT Annual Meeting 2025
    News
  15. Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
    Results

See a number that looks wrong?